Methods of Treating Heavy Menstrual Bleeding

ChangeBridge: Patent Apps - Pharma (A61K)

Published April 2nd, 2026

Detected April 3rd, 2026

Summary

USPTO published patent application US20260091041A1 for methods of treating heavy menstrual bleeding with or without uterine fibroids. The application claims a method using compound 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or salts thereof in combination with estrogens and progestogens. Fifteen inventors are named including Kristof Chwalisz, Jane Castelli-Haley, and others.

View original document View source feed page

What changed

USPTO published application US20260091041A1 claiming a method of treating heavy menstrual bleeding in subjects with or without uterine fibroids by administering an effective amount of a specific compound in combination with estrogens and progestogens. The application (serial no. 19301199) was filed August 15, 2025, and names 15 inventors. CPC classifications include A61K 31/57, A61K 31/513, and A61P 15/00.

This is a patent application publication, not a regulatory requirement. Pharmaceutical companies and drug manufacturers in the women's health or fibroids treatment space should monitor this application to assess freedom-to-operate considerations for competing or complementary therapies. Legal and IP teams may review for potential licensing or development implications. No compliance actions or deadlines are associated with this document.

Source document (simplified)

← USPTO Patent Applications

Methods of Treating Heavy Menstrual Bleeding

Application US20260091041A1 Kind: A1 Apr 02, 2026

Inventors

Kristof Chwalisz, Jane Castelli-Haley, Oscar Antunez Flores, Keith Gordon, Rita Jain, Juki Wing-Keung Ng, Janine D. North, Charlotte D. Owens, Hannah Palac, Paul M. Peloso, Michael C. Snabes, Ahmed M. Soliman, James W. Thomas, Mohamad Shebley

Abstract

The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.